|
LIVE WEBINAR: Wednesday, May 18, 2022, 5:00 PM – 6:00 PM Eastern Time
What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial ParticipationA 2-Part Complimentary NCPD Webinar SeriesGastroesophageal CancersJoin us on Wednesday, May 18th for this NCPD-accredited webinar Faculty
Kristen K Ciombor, MD, MSCI Associate Professor of Medicine Division of Hematology/Oncology Vanderbilt-Ingram Cancer Center Nashville, Tennessee
Jessica Mitchell, APRN, CNP, MPH
Assistant Professor of Oncology Mayo Clinic College of Medicine and Science Rochester, Minnesota Moderator Neil Love, MD Research To Practice Miami, Florida Wednesday, May 18, 2022 Topics to Be Discussed MODULE 1: What I Tell My Patients About First-Line Therapy for Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Cancer MODULE 2: What I Tell My Patients About the Tolerability of Immune Checkpoint Inhibitors in Combination with Chemotherapy MODULE 3: What I Tell My Patients About First-Line Therapy for Metastatic HER2-Positive Gastric or GEJ Cancer MODULE 4: What I Tell My Patients About the Selection and Sequencing of Therapy for Relapsed/Refractory (R/R) HER2-Negative Gastric and GEJ Cancer MODULE 5: What I Tell My Patients About the Tolerability of Ramucirumab and TAS-102 MODULE 6: What I Tell My Patients About the Selection and Sequencing of Therapy for R/R HER2-Positive Gastric Cancer MODULE 7: What I Tell My Patients About the Incidence and Management of Toxicities with T-DXd (Trastuzumab Deruxtecan) MODULE 8: What I Tell My Patients About the Management of Metastatic Esophageal Cancer MODULE 9: What I Tell My Patients About Adjuvant Anti-PD-1 Antibody Therapy for Esophageal Cancer MODULE 10: What I Tell My Patients About Promising Investigational Strategies for Gastroesophageal Cancers Target Audience
Accreditation Statement Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — Ms Mitchell has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities: Dr Ciombor – Advisory Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Personalis Inc, Pfizer Inc, Replimune; Consulting Agreements: Merck, Pfizer Inc, Seagen Inc; Contracted Research: Bristol-Myers Squibb Company, Calithera Biosciences, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Incyte Corporation, Merck, NuCana, Pfizer Inc. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME and NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc. RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from Astellas and Lilly. |